What the low impact of Humira biosimilars teaches us about drug prices

Almost everyone seems to agree that drug prices are too high. But that agreement stops when it comes to the question of why they’re so high, and the resultant question of how to bring them down.

Goodroot CEO Mike Waterbury and Nuwae Health CEO Ralph Pisano discuss how the community of Goodroot companies, including Nuwae, are attacking that issue from different angles.

They also get into one particular illustrative example of the problem – the recent availability of Humira biosimilars, which, according to Goodroot’s research, is unlikely to actually lower prices very much.

They also discuss other efforts to address drug prices, including Mark Cuban’s CostPlus Drugs and the United States Inflation Reduction Act.

You can listen to episode 82 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series - in iTunes, Spotify, Stitcher, and Podbean.